Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Merus N.V. (NASDAQ: MRUS).

Full DD Report for MRUS

You must become a subscriber to view this report.


Recent News from (NASDAQ: MRUS)

Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell
UTRECHT, The Netherlands, May 15, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the unique mechanism of action (MOA) of MCLA-128, the Company’s most...
Source: GlobeNewswire
Date: May, 15 2018 07:00
Blog Exposure - VIVUS to Acquire Janssen Pharma's PANCREAZE(R) Capsules in the United States and Canada
Stock Monitor: Merus Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on VIVUS, Inc. (NASDAQ: VVUS ). If you want access to this report all you need to do is sign up now by clicking the following link www.a...
Source: ACCESSWIRE IA
Date: May, 03 2018 07:30
Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017
- Phase 2 combination trial in two metastatic breast cancer (MBC) populations initiated for Merus’ most advanced bispecific antibody candidate, MCLA-128 - - Strategic collaboration announced with Simcere Pharmaceutical Group for multiple bispecific antibodies; expanded collabora...
Source: GlobeNewswire
Date: April, 26 2018 07:00
Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018
UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company will report full year 2017 financial results on Thu...
Source: GlobeNewswire
Date: April, 19 2018 07:00
Analysis: Positioning to Benefit within HudBay Minerals, IRHYTHM TECH, TechTarget, Mercury, Merus N.V, and Tecnoglass - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of HudBay Minerals Inc (NYSE:HBM), IRHYTHM TECH (NASDAQ:IRTC), TechTarget, ...
Source: GlobeNewswire
Date: April, 09 2018 08:20
Merus and the Vall d'Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer
UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), and the Vall d’Hebron Institute of Oncology (VHIO), a leading comprehensive canc...
Source: GlobeNewswire
Date: March, 20 2018 07:00
Report: Exploring Fundamental Drivers Behind Gladstone Commercial, IRHYTHM TECH, Jounce Therapeutics, CoStar Group, Tecnoglass, and Merus N.V - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Gladstone Commercial Corporation (NASDAQ:GOOD), IRHYTHM TECH (NASDAQ:IRT...
Source: GlobeNewswire
Date: March, 16 2018 07:45
Ono Pharma exercises option for Merus Biclonics technology for autoimmune bispecific antibody
Merus N.V. (NASDAQ: MRUS ) announces that collaboration partner Ono Pharmaceutical ( OTC:OPHLF )( OTCPK:OPHLY ) has exercised its option to enter into a new research and license agreement to use its Biclonics technology platform to develop a bispecific antibody targeting autoimmune disorde...
Source: SeekingAlpha
Date: March, 14 2018 07:28
Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases
UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ono Pharmaceutical Co., LTD. (Osaka, Japan, ‘Ono&#x...
Source: GlobeNewswire
Date: March, 14 2018 07:00
Merus' Intellectual Property Portfolio Expands with Two New Patents
UTRECHT, The Netherlands, March 13, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced that it has expanded its intellectual property portfolio with two newly...
Source: GlobeNewswire
Date: March, 13 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1717.520717.8217.9717.5215,781
2018-02-2617.9017.9118.114317.8535,967
2018-02-2318.0617.9718.1017.9628,290
2018-02-2218.0117.9718.1417.9030,785
2018-02-2117.8617.9418.1217.8035,285

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-259,53111,64181.8744Short
2018-05-2412,79717,60872.6772Short
2018-05-237515,81912.9060Cover
2018-05-223,8617,20153.6176Short
2018-05-212,36711,81320.0372Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MRUS.


About Merus N.V. (NASDAQ: MRUS)

Logo for Merus N.V. (NASDAQ: MRUS)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $330,113,118 - 05/11/2018
  • Issue and Outstanding: 19,429,848 - 12/31/2017

 


Recent Filings from (NASDAQ: MRUS)

Registration statement for certain foreign private issuers offered for certain transactions
Filing Type: F-3Filing Source: edgar
Filing Date: May, 15 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: April, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 05 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: February, 28 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 23 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 08 2018

 

 


Daily Technical Chart for (NASDAQ: MRUS)

Daily Technical Chart for (NASDAQ: MRUS)


Stay tuned for daily updates and more on (NASDAQ: MRUS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: MRUS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MRUS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of MRUS and does not buy, sell, or trade any shares of MRUS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/